Drug Search Results
More Filters [+]

Cefilavancin

Alternative Names: cefilavancin, td-1792, td1792, td 1792
Latest Update: 2021-04-30
Latest Update Note: PubMed Publication

Product Description

Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cefilavancin)

Mechanisms of Action: Cell Wall Synthesis Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Theravance Biopharma
Company Location: GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Company CEO: Rick E Winningham
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cefilavancin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Cellulitis|Staphylococcal Skin Infections|Skin Diseases, Infectious|Staphylococcal Infections|Communicable Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00442832

P2

Completed

Staphylococcal Skin Infections|Cellulitis|Communicable Diseases|Skin Diseases, Infectious|Staphylococcal Infections

2007-05-01

24%

Recent News Events